FDA recommends scheduling of 7-OH, states health concerns of 7-OH and its distinction from the kratom plant leaf WASHINGTON, DC, July 31, 2025 (EZ Newswire) -- Today,  American Kratom Association (AKA) issued a formal policy advisory to the attorneys general in every state that has enacted a Kratom Consumer Protection Act (KCPA), urging them to take immediate enforcement action against the unlawful sale of highly dangerous 7-hydroxymitragynine (7-OH) products that are misleadingly marketed as kratom. This action comes in response to the recent decision by the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) to recommend that 7-OH be placed into Schedule I of the Controlled Substances Act, citing overwhelming evidence of its opioid-like effects, high abuse potential, and serious risks to consumer safety. “Let’s be clear: 7-OH is not kratom,” said Mac Haddow, senior fellow on public policy for the American Kratom Association.